JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the champion debt-free penny stocks to bargain close now. On December 17, JPMorgan upgraded Recursion Pharmaceuticals (NASDAQ:RXRX) to an Overweight from Neutral and raised the terms people to $11 from $10.

The upgrade follows promising objective trials evaluating the MEK 1/2 inhibitor REC-4881 for the attraction of Familial Adenomatous Polyposis (FAP). The TUPELO proceedings showed that 75% of evaluable patients showed a important simplification successful full polyp burden.

“The durable polyp load simplification demonstrated by REC-4881—especially the sustained effect seen astatine Week 25, 12 weeks aft completing therapy—is highly encouraging for the FAP community,” said Jessica Stout, D.O., Assistant Clinical Professor, University of Utah School of Medicine, and Principal Investigator of the TUPELO study.

According to JPMorgan, the institution is staring astatine a tremendous accidental with REC-4881 with estimated highest income of much than $1 billion. Additionally, the concern institution has touted the company’s different campaigner drug, REC-617, a CDK7 inhibitor showing aboriginal anti-tumor enactment successful platinum-resistant ovarian cancer.

The affirmative objective trials enactment Recursion’s semipermanent prospects, arsenic the institution has generated implicit $400 cardinal successful milestone payments from pharmaceutical partnerships.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is simply a clinical-stage institution that uses a operation of artificial quality (AI), automation, and experimental biology to accelerate the find and improvement of caller drugs.

While we admit the imaginable of RXRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Blue Chip Stocks to Buy for 2026 and 10 Best Metal Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.